ArticleOncology research2026
Integrated Global Phosphoproteomic, Bioinformatic, and Machine Learning Analysis Reveals Regulatory Networks of TOP1, TOP2A, TOP2B, and C1orf35 in Hepatocellular Carcinoma (HCC).
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Validated stability indicating reverse phase liquid chromatography method for oxcarbazepine and its degradation products with greenness evaluation.Scientific reports · 2026Article
- Mechanism-Base Pharmacokinetic-Pharmacodynamic Modeling of Cefquinome AgainstMedical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, largely due to late diagnosis, molecular heterogeneity, and limited prognostic biomarkers. Aberrant protein phosphorylation plays a critical role in cancer progression by regulating DNA damage response, cell cycle control, and signaling pathways; however, the prognostic relevance of phosphorylation events in key DNA topology-related proteins remains incompletely understood. This study aimed to investigate the prognostic significance of phosphorylation of TOP1, TOP2A, TOP2B, and C1orf35 in HCC and to characterize their associated molecular features to identify potential diagnostic and therapeutic biomarkers. Methods: Publicly available HCC phosphoproteomic and proteomic datasets were analyzed to identify significantly upregulated phosphorylation sites of TOP1, TOP2A, TOP2B, and C1orf35. Integrated bioinformatics and machine learning approaches were applied, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), protein-protein interaction (PPI) network analysis, drug-gene interaction analysis, and survival analyses (overall and disease-free survival). Results: A total of 11,547 phosphorylation sites corresponding to 4043 phosphoproteins were quantified from 159 HCC patients. Phosphorylation of TOP1, TOP2A, TOP2B, and C1orf35 was significantly upregulated. Enriched pathways included DNA damage response, homologous recombination repair, cell cycle regulation, SUMOylation, and TP53 signaling. PPI analysis identified these proteins as highly interconnected hub nodes. Elevated expression was significantly associated with poor clinical outcomes. Conclusions: Phosphorylated TOP1, TOP2A, TOP2B, and C1orf35 are strongly associated with HCC progression and poor prognosis, highlighting their potential as prognostic biomarkers and therapeutic targets. These insights not only enhance our understanding of the complex molecular mechanisms underlying HCC but also offer promising avenues for the identification of novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.